Drug Profile
AGN 4326
Alternative Names: ALRT 326Latest Information Update: 18 May 2020
Price :
$50
*
At a glance
- Originator Allergan
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 27 Jun 2001 Discontinued-Preclinical for Type-2 diabetes mellitus in USA (Unknown route)
- 26 Feb 2001 No-Development-Reported for Type-2 diabetes mellitus in USA (Unknown route)